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Abstract
Tobacco and marijuana are some of the most common prenatal substance exposures worldwide. 
The social acceptability and political landscape of marijuana and its potency have changed 
dramatically in the last two decades leading to increased use by pregnant women. Despite 
evidence for increasing marijuana use and high rates of co-use of tobacco (TOB) and marijuana 
(MJ) during pregnancy, the impact of prenatal exposure to each substance is typically studied in 
isolation. We investigated the influence of co-exposure to TOB and MJ on infant neurobehavioral 
development over the first postnatal month. Participants were 111 mother-infant pairs from a low-
income, diverse sample (Mean age=25±5; 54% minorities). TOB and MJ use were assessed by 
Timeline Followback interview with biochemical confirmation. Three groups were identified: (a) 
prenatal MJ+TOB, (b) prenatal TOB only, (c) controls. Newborn neurobehavior was assessed at 
seven time points over the first postnatal month using the NICU Network Neurobehavioral Scale. 
MJ+TOB-exposed infants showed decreased ability to selfsoothe (Self-regulation) and attend to 
stimuli (Attention), and increased need for examiner soothing (Handling) and low motor activity 
1Non-standard Abbreviations: TOB - Tobacco - MJ - Marijuana - THC - Δ9-tetrahydrocannabinol - BAM BAM - Behavior and 
Mood in Babies and Mothers study - NNNS - NICUNetwork Neurobehavioral Scale - ETS - environmental tobacco smoke - CO - 
carbon monoxide - SES - socioeconomic status r for publication
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(Lethargy) versus unexposed infants. Despite low levels of MJ use in MJ+TOB co-users, co-
exposure was associated with nearly double the impact on infant self-soothing and need for 
examiner soothing versus TOB-exposure alone. Effects of MJ+TOB co-exposure appeared more 
pronounced for daughters than for sons. Although results are preliminary, they highlight additional 
risk from dual exposure to MJ+TOB vs. TOB exposure alone, particularly for daughters. Results 
also highlight the critical importance of investigating prenatal exposures in concert and the need 
for intervention efforts to address MJ co-use in pregnant TOB users.
Keywords
pregnancy; marijuana; tobacco; infant; behavior; NNNS
1. Introduction
Maternal tobacco (TOB) use during pregnancy remains an enormous public health problem 
in the US and worldwide. Despite large-scale public education campaigns, approximately 
one of every ten infants in the US is born exposed to tobacco (Curtin and Matthews, 2016; 
Drake et al., 2018; Tong et al., 2013; U.S. Department of Health and Human Services, 
2014). Infants born to less educated, poor, and underserved mothers show disproportionately 
higher rates of TOB exposure (up to ~2 in 10 infants born exposed) (Tong et al., 2013). As 
documented in the 2014 Surgeon General’s Report, prenatal exposure to cigarette smoking 
is considered causally linked to increased risk for infant morbidity and mortality including 
low birth weight, preterm birth, and sudden infant death syndrome (U.S. Department of 
Health and Human Services, 2014). In older children and adolescents, suggestive 
associations were shown between prenatal TOB exposure and altered neurobehavioral 
development, including disruptive behaviors/conduct disorder, attention deficits/attention 
deficit hyperactivity disorder, and smoking/nicotine dependence (Gaysina et al., 2013; 
Huang et al., 2018; Ruisch et al., 2018; Shenassa et al., 2015; U.S. Department of Health 
and Human Services, 2014).
Maternal marijuana use during pregnancy is also one of the most widespread prenatal drug 
insults in the US and the world (Center for Behavioral Health Statistics and Quality, 
2015;World Health Organization, 2016). The social acceptability and political landscape of 
marijuana (MJ) have changed dramatically in the US in the last decade, accompanied by 
expanding legalization, decriminalization, and medicalization (Pew Research Center, 2015). 
Paralleling increased societal acceptance of MJ, rates of MJ use by pregnant women 
increased by sixty-two percent between 2002 and 2014, with current estimates of between 1 
and 2 infants in every 20 born exposed, and increased rates in poor, young, and less-
educated mothers (Brown et al., 2017; Ko et al., 2015; Substance Abuse and Mental Health 
Services, 2012; Substance Abuse and Mental Health Services Administration, 2014). 
Further, potency of Δ9-tetrahydro-cannabinol (THC), the primary psychoactive ingredient in 
MJ, has increased 300% since 1995 (ElSohly et al., 2016; Mehmedic et al., 2010). The 
impact of prenatal MJ exposure on offspring development has received less research 
attention relative to tobacco. A recent meta-analysis found no effects of prenatal MJ 
exposure on preterm birth, but demonstrated a 77% increased risk for low birthweight in MJ-
Stroud et al. Page 2













exposed infants (Gunn et al., 2016); however, it was not possible to rule out effects on low 
birthweight due to other substance exposures. Longer-term studies have revealed some 
evidence for associations between prenatal MJ and impairments in attention and inhibitory 
control, impulsivity and hyperactivity, and increased risk of MJ use in child, adolescent, and 
young adult offspring (Day et al., 2006; Day et al., 2011; Day et al., 1994; Fried, 2002; 
Goldschmidt et al., 2012; Smith et al., 2006; Smith et al., 2016).
Approximately twenty to thirty percent of pregnant women who use TOB endorse MJ couse 
(Chabarria et al., 2016; Coleman-Cowger et al., 2017; Ko et al., 2015). Rates of TOB co-use 
among pregnant women who use MJ are even higher—approximately two-thirds to three 
fourths of pregnant MJ users endorse TOB co-use (Chabarria et al., 2016; Coleman-Cowger 
et al., 2017; El Marroun et al., 2008; Ko et al., 2015). In non-pregnant populations, MJ+TOB 
co-use was associated with worse health outcomes, including increased risk of both MJ and 
TOB use disorders, poorer MJ and TOB cessation outcomes, increased psychiatric 
conditions, and increased respiratory dysfunction (Agrawal et al., 2012; Peters et al., 2012; 
Peters et al., 2014; Rabin and George, 2015). In pregnant women, MJ+TOB co-use was 
associated with increased maternal (e.g., asthma and pre-eclampsia) and neonatal health 
risks (preterm birth, decreased birthweight and head circumference), increased risk for 
maternal psychiatric and alcohol use disorders, increases in other drug and poly-tobacco use, 
and difficulty with TOB cessation (Chabarria et al., 2016; Coleman-Cowger et al., 2017; 
Emery et al., 2016; Gray et al., 2010).
The impact of MJ+TOB on fetal development may be mediated by THC/cannabinoids and 
nicotine. Nicotine and THC freely cross the placenta and enter fetal circulation (Little and 
VanBeveren, 1996; Luck et al., 1985). In preclinical models, both prenatal nicotine and THC 
administration result in persistent alterations in neuronal development—nicotine via 
nicotinic acetylcholine receptors and disruption of brain cell replication and differentiation 
and THC via cannabinoid receptors and disruption of neuronal wiring (England et al., 
2017a; Levin and Slotkin, 1998; Parsons and Hurd, 2015; Richardson et al., 2016). Both 
prenatal nicotine and THC also result in widespread disruption of neurotransmitter systems, 
including serotonergic, GABAergic, and dopaminergic systems (England et al., 2017a; 
Morena et al., 2016). Although to our knowledge, no preclinical models have investigated 
joint effects of prenatal nicotine and THC exposure, it is plausible that disruption of 
neuronal development via both nicotinic and endocannabinoid pathways may result in 
additive or synergistic effects of prenatal TOB+MJ on offspring neurobehavioral 
development.
Despite plausible neurobiological mechanisms and evidence for increased maternal and 
neonatal health risks from prenatal MJ+TOB exposure, few studies examined the impact of 
prenatal co-use on infant neurobehavioral development. Eiden et al. found that MJ+TOB 
coexposure was associated with less adaptive autonomic regulation at nine months, which 
was then associated with diminished emotion regulation at twenty-four months (Eiden et al., 
2018). Schuetze et al. investigated prenatal MJ+TOB co-exposure effects on infant reactivity 
and regulation in the context of maternal and fetal mediators (maternal stress, anger, fetal 
growth) (Schuetze et al., 2018). No direct effects were found; however, prenatal MJ+TOB 
exposure was associated with altered fetal growth, which was then associated with altered 
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regulation and negative affect at 9 months. Finally, El Marroun et al. found effects of 
prenatal MJ exposure on offspring inattention and aggressive behavior in 18-month old 
infants, the majority of whom were also exposed to tobacco (El Marroun et al., 2011).
To our knowledge, no studies have explicitly examined the impact of prenatal MJ+TOB 
coexposure on newborn neurobehavioral development over the first postnatal month despite 
the importance of this period for (1) establishment of parent-infant attachment, (2) 
documenting the earliest unfolding developmental pathways leading to long-term child 
behavioral outcomes, and (3) investigating the impact of prenatal exposures prior to long-
term exposure to second-hand tobacco/MJ smoke. Instead, effects of prenatal exposure to 
MJ or TOB on newborn neurodevelopment have typically been studied in isolation. Because 
the goal of many neurodevelopmental studies is to determine fetal neurotoxicity of a specific 
substance, typical studies include statistical control for co-exposures, but little systematic 
investigation of the potential unique or additive/synergistic impact of co-exposures on 
offspring outcomes (Lester and Lagasse, 2010).
Multiple prior studies investigated effects of prenatal TOB alone on newborn neurobehavior. 
In the early newborn period, TOB-exposed infants have shown increased irritability, 
excitability, and need for external soothing versus unexposed infants (Godding et al., 2004; 
Law et al., 2003; Mansi et al., 2007; Stroud et al., 2009a). In the later newborn period and in 
studies investigating neurobehavior across the first postnatal month, TOB-exposed infants 
showed decreased ability to self-soothe (self-regulation), increased need for external 
soothing (need for handling), decreased attention to stimuli (attention/orientation), and 
alterations in motor activity (including increased lethargy and arousal) (Espy et al., 2011; 
Stroud et al., 2016; Stroud et al., 2009b; Yolton et al., 2009). A much smaller number of 
studies examined links between prenatal MJ and newborn neurobehavior. In a middle-class, 
low risk sample, exposure to prenatal MJ was associated with poorer habituation to visual 
stimuli, increased arousal, excitability, and irritability, and decreased ability to self-soothe in 
the early newborn period (Fried, 1980; Fried and Makin, 1987). These effects were 
corroborated by studies designed to investigate other perinatal risk factors (prenatal cocaine 
exposure, adolescent pregnancy) (Coles et al., 1992; de Moraes Barros et al., 2006; Lester et 
al., 2002), but were not replicated in a high risk MJ-exposed sample (Richardson et al., 
1989) or in a study of MJ exposure in Jamaican infants (Hayes et al., 1988).
Sex-specific effects of both prenatal TOB and prenatal MJ on offspring neurobehavior have 
been reported in a small number of studies. In older offspring, there is some evidence that 
prenatal TOB exposure exerts a more pronounced impact on offspring behavioral 
dysregulation and disruptive behavior disorders in sons, whereas the impact of prenatal TOB 
exposure on offspring tobacco and other drug use/disorders (including cannabis, cocaine), 
was more pronounced in daughters (Brennan et al., 2002; Coles et al., 2012; Fergusson et 
al., 1998; Kandel et al., 1994; Stroud et al., 2014b; Weissman et al., 1999). Further, prenatal 
MJ exposure led to increased infant inattention and aggression at 18 months in daughters but 
not sons (El Marroun et al., 2011). Sex-specific effects of both prenatal THC and prenatal 
nicotine exposure were also documented in animal models (Bonnin et al., 1996; Cross et al., 
2017).
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1.1. The Present Study
Despite evidence for overlapping alterations in newborn neurobehavior (including 
selfregulation, attention and motor activity) from TOB and MJ examined in isolation, to our 
knowledge, no studies investigated the impact of MJ+TOB co-use on newborn 
neurobehavior.
Thus, our first goal was to investigate the impact of prenatal MJ+TOB vs. TOB only versus 
no substance exposure on newborn self-regulation, need for external handling, attention, and 
lethargy over the first postnatal month. We hypothesized that MJ+TOB-exposed newborns 
would show altered ability to self-regulate, worse attention, and increased lethargy versus 
unexposed infants; we also explored the hypothesis that co-exposed infants would show 
worse neurobehavioral outcomes versus TOB-exposed infants. Given evidence of sex-
specific effects of prenatal TOB and MJ in some prior studies of older offspring, our second 
goal was to explore the sex-specific impact of prenatal MJ+TOB vs. TOB only vs. no 
substance exposure on newborn neurobehavior.
2. Material and Methods
2.1. Study Design.
As shown in Figure 1, the Behavior and Mood in Babies and Mothers (BAM BAM) study 
was a prospective study of effects of maternal tobacco use in pregnancy on fetal and infant 
neurobehavior (Stroud et al., 2018; Stroud et al., 2014a; Stroud et al., 2016). Pregnant 
mothers were recruited from obstetrical offices, health centers, and community postings 
primarily during first and second trimester and were enrolled during late second or third 
trimester of pregnancy (M=31 weeks gestation, SD=2) between 2006 and 2010. Mothers 
completed between 2 and 4 (M=3, SD=1) interview sessions during second and third 
trimesters of pregnancy and at delivery (26–42 weeks gestation) depending on the timing of 
study enrollment and their availability for multiple assessments. Fifty percent completed 4 
interview sessions; 45% completed 3 interviews, and 5% completed 2 interviews. 
Specifically, interview sessions took place at 31±2, 35±1, 36±1 weeks gestation and at 1±1 
days post-delivery. Mean number of weeks between interview sessions was 3.5 weeks 
(SD=1.4). Meconium was collected following delivery to assess biomarkers for nicotine and 
other substances. Postnatal follow-up sessions included infant neurobehavioral examinations 
(NICU Network Neurobehavioral Scale; NNNS) and saliva samples to determine infant 
exposure to nicotine. Day 1 and Day 32 postnatal sessions also included maternal interview 
questions. Postnatal follow-up sessions were conducted up to 7 times over the first postnatal 
month (Med=7, M=6) at days 0 (M=8 hours), 1, 2, 4, 5, 11, and 32 (SDs=0.1, 0.3, 0.3, 0.6, 
0.4, 2.3, and 3.1 days, respectively). All day 0 and 1 NNNS were conducted in the hospital, 
56% of day 2—4 NNNS were conducted in the hospital; 99% of day 5—32 NNNS were 
conducted at participants’ homes. Postnatal time points were selected to conduct a detailed 
examination of rapid neurodevelopment and potential nicotine withdrawal over the first 5 
postnatal days, followed by longitudinal assessment over the remainder of the month (days 
11 and 32).
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Participants in the current study were a subsample from the BAM BAM Study (above). 
Maternal exclusion criteria included age <18 or >40, regular illicit drug use besides MJ 
(meconium confirmed), involvement with child protective services, and serious medical 
conditions (e.g., pre-eclampsia, severe obesity). Infants were healthy singletons born >36 
weeks gestational age (GA) with no congenital anomalies or serious medical conditions. All 
procedures were reviewed and approved by local Institutional Review Boards.
One hundred forty-eight pregnant women ages 18–40 enrolled in the study. Of these, six 
were excluded for regular opiate or cocaine use, two for involvement with child protective 
services, five for maternal medical conditions, and six for delivery ≤ 36 weeks gestation. Ten 
infants who did not have neurobehavior data were excluded from analyses. Four participants 
who were missing maternal-report data regarding MJ use and four participants who used MJ, 
but not TOB, were excluded from analyses given our focus on MJ+TOB co-use. The final 
analytic sample (n=111) included 24 MJ+TOB users, 45 tobacco-only (TOB) users and 42 
biochemically-verified controls. The MJ+TOB group included participants whose maternal 
report or biomarkers were positive for TOB and whose maternal report or biomarkers were 
positive for MJ. The TOB group included participants whose maternal report or biomarkers 
were positive for TOB, and whose maternal report and biomarkers were negative for MJ. 
The Control group included participants whose maternal report and biomarkers were 
negative for both TOB and MJ. Infant offspring included 51 daughters and 60 sons.
2.3. Procedures
2.3.1. Maternal Interviews.—During each interview, mothers completed the Timeline 
Followback (TLFB) interview (Robinson et al., 2014), a calendar/anchor-based assessment 
of tobacco, marijuana, and other substance use, adapted to assess use over pregnancy and 
three months prior to conception. Mothers also provided saliva samples for cotinine 
determination. Demographic characteristics, caffeine consumption, environmental tobacco 
smoke (ETS) exposure, health and pregnancy history and depression were also assessed. 
Finally, maternal weight and expired breath carbon monoxide were measured during third 
trimester. TLFB other substance use, caffeine, ETS, health and pregnancy history, 
depression, and weight were utilized to describe the sample and were also tested as potential 
confounders (Section 2.4.). Cotinine and carbon monoxide concentrations were utilized to 
examine differences between TOB and MJ+TOB groups.
2.3.2. Infant Neurobehavior over the First Postnatal Month.—The NICU 
Network Neurobehavioral Scale (NNNS) is an infant neurobehavioral assessment designed 
to reveal subtle differences in high-risk and substance-exposed infants (Lester et al., 2004; 
Tronick and Lester, 2013). The NNNS follows a standard but flexible (based on infant 
behavior) administration sequence that starts with pre-examination observation followed by 
neurologic and behavioral components (Lester et al., 2004; Tronick and Lester, 2013). The 
exam includes exposure to auditory, visual, social and non-social stimuli and lasts 
approximately 30 minutes (M=27 min; SD=5 min). NNNS subscales of focus for the present 
study include: Self-Regulation, Handling (need for external soothing of the infant to 
maintain a quiet alert state), Lethargy, and Attention. All NNNS were administered by 
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certified examiners who were blind to maternal substance exposure during pregnancy. Saliva 
samples collected at the time of the final NNNS examination (Day 32) were utilized to 
determine infant exposure to nicotine via environmental tobacco smoke (ETS) or breast 
milk. Time between last feeding and start of NNNS was recorded for use as an a priori 
covariate in multivariate models.
2.4. Bioassays
2.4.1. Saliva cotinine.—Saliva cotinine is a reliable biomarker for nicotine 
concentrations (Jarvis et al., 1987). Maternal and infant saliva samples were frozen until 
analysis by Salimetrics (www.Salimetrics.com) using highly-sensitive enzyme 
immunoassay. Intra and inter-assay coefficients of variation were 6.4% and 6.6%.
2.4.2. Breath Carbon Monoxide—Expired alveolar carbon monoxide (CO) is a 
biomarker of recent exposure to TOB or MJ combustion (Sandberg et al., 2011). CO 
concentrations in expired breath samples were measured in duplicate using the Bedfont 
Micro 4 Smokerlyzer (Bedfont® Scientific Ltd).
2.4.3. Meconium nicotine and cannabinoid biomarkers—Meconium was 
analyzed for nicotine markers (nicotine, cotinine, trans-3′hydroxycotinine), cannabinoid 
markers (Δ9-tetrahydrocannabinol (THC), 11-nor-9-carboxyTHC, cannabinol, 11-hydroxy-
THC, di-OH-THC), opiates, cocaine, and amphetamines via EMIT screens, tandem liquid 
chromatography mass spectrometry or gas chromatography mass spectroscopy confirmation 
(Gray et al., 2009b; Moore et al., 1998). Samples from all participants were negative for 
cocaine, opiates, and amphetamines. Samples with nicotine or cannabinoid markers ≥10 
ng/g were considered positive for nicotine and/or cannabinoids (Gray et al., 2009a).
2.5. Measurement of Potential Confounders
Multiple potential confounders of the association between prenatal TOB and MJ+TOB and 
infant outcomes were measured. Maternal demographics: age, race/ethnicity (% 
NonHispanic White), Hollingshead socioeconomic status (SES; low SES=Hollingshead ≥ 
4); and pregnancy history: gravida, parity, were assessed by maternal report. Maternal 
gestational medical conditions, e.g., hypertension and diabetes were determined by maternal 
report and medical chart review. Weight gain over pregnancy was assessed by maternal 
report (prepregnancy) and study measurement (35±1 weeks). Maternal depressive symptoms 
were assessed by structured interview using the 21-item Hamilton Depression Rating Scale 
(HDRS) (Hamilton, 1960). The HDRS is the most commonly used measure of depression 
with demonstrated convergent validity, sensitivity/specificity, and test retest reliability 
(Hotopf et al., 1998;Mottram et al., 2000; Rehm and O'Hara, 1985; Reynolds and Kobak, 
1995; Williams, 1988). Maternal alcohol use was assessed through TLFB interview 
(Robinson et al., 2014). Maternal caffeine use and environmental tobacco smoke (ETS) 
exposure were assessed by structured interview; infant ETS exposure was assessed by infant 
saliva cotinine. Infant characteristics: sex, delivery mode, GA at birth, small for GA (SGA; 
birth weight <10th percentile for GA), and Apgar were assessed by medical chart review. 
Feeding method (breast vs. bottle) was assessed by maternal report.
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2.6.1. Testing of potential confounders—Each of the potential confounders 
described in Section 2.4 was first tested individually in relation to exposure group (MJ
+TOB, TOB, Control) using Kruskal-Wallis ANOVA as omnibus tests for continuous 
confounders, and by Chi-square and Fisher’s exact tests (as appropriate) for discrete 
confounders (See Table 1). Potential confounders that showed significant differences across 
exposure groups (omnibus ps<.05) were further evaluated for associations with NNNS 
outcomes. Those showing significant associations with individual NNNS subscales (ps<.05) 
were included in the respective regression models (See below and Table 2). Specifically, 
feeding method (any breast-feeding) was a significant confounder for the NNNS Self-
Regulation and Handling models; infant ETS and maternal depressive symptom exposure 
were significant confounders for the NNNS Lethargy and Attention models. All regression 
models also included time since feeding (log-transformed), an important determinant of 
infant neurobehavior, as an a priori covariate.
2.6.2. Longitudinal regression modeling.—Outcomes exhibiting significant 
skewness (NNNS Handling, NNNS Lethargy) were symmetrized via a logarithmic 
transformation. Effects of substance-exposure group on infant neurobehavior (NNNS Self-
Regulation, Handling, Lethargy, Attention) over the first postnatal month were investigated 
using Generalized Least Squares regression modeling (Fitzmaurice et al., 2011). Generalized 
least squares regression modeling is an extension of repeated measures analysis of 
covariance which allows for: (a) heteroscedastic variances (i.e., unequal variance across 
NNNS visits), (b) correlations between NNNS visits for the same participant depending on 
their separation in time, (c) incorporation of time-varying covariates (e.g., time since feeding 
for each NNNS visit), and (d) intermittent missingness in NNNS visits over time. 
Specifically, although 111 infants contributed NNNS exams on at least one visit, NNNS 
exams on Days 0, 1, 2, 3, 5, 11, and 32 were missing for 14, 6, 10, 20, 23, 15, and 18 infants 
respectively (See Figure 1). Analyses for each outcome of interest were conducted using the 
nlme library of R 3.4.2 (https://cran.r-project.org) assuming group-specific variances and a 
continuous-time first-order autocorrelation. Residual standard deviations calculated in the 
Control group were used to convert group differences into effect sizes.
In the present analyses, substance exposure group was the between-subjects factor and infant 
age at the NNNS (log-transformed) was the within-subjects factor. Overall differences 
between the exposure groups in both outcome levels at the first NNNS exam (intercept) and 
with respect to infant age at NNNS exam over the first postnatal month (linear slope) were 
tested using multivariate Wald tests with 2 degrees of freedom. Significant omnibus 
association tests were followed by examination of pairwise contrasts (MJ+TOB vs. Control, 
TOB vs. Control, and MJ+TOB vs. TOB). Both omnibus and pairwise tests were adjusted 
for significant confounders. All associations were investigated in an overall model including 
all participants, and in identical models stratified by infant sex. Significant confounders from 
the overall sample were also utilized for sex-stratified models.
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Descriptive statistics for the overall sample and stratified by substance-exposure group are 
presented in Table 1. The sample was primarily low socioeconomic status (55% ≤ high 
school education; 57% unemployed; 48% annual income <$20,000), and racially/ethnically 
diverse (18% African-American, 25% Hispanic, and 11% Multiracial/Other; 46% Non-
Hispanic White). Infants ranged in age from 0–43 days. There were no significant 
differences in average cigarettes per day, or maternal cotinine or CO concentrations between 
TOB-only and MJ+TOB users. The 45 TOB-only users reported an average of 10±7, 6±6, 
and 5±6 cigarettes per day, and the 24 MJ+TOB users reported an average of 10±8, 6±6, and 
4±4 cigarettes per day during first, second, and third trimesters. MJ+TOB users endorsed an 
average of 24 days of MJ use (SD=24) over pregnancy, with 24±24, 1±1, and 0.04±0.20 
days of use during each trimester. Types of MJ use endorsed included: joints (33%), blunts 
(33%), multiple methods (13%; joints + blunts; bowls + joints) and unknown (8%), as well 
as three MJ+TOB users (13%) who denied MJ use on the TLFB but had positive meconium 
cannabinoids markers.
MJ+TOB and TOB-only mothers were more likely to be low SES, to be exposed to ETS, 
and showed greater depressive symptoms than Controls; their infants were less likely to be 
breast fed and showed increased cotinine vs. Controls. MJ+TOB users were more likely to 
use >1 drink/week than Controls; TOB-only users were more likely to use caffeine than 
Controls. Of maternal and infant characteristics which differed by exposure group, those that 
were also associated with individual NNNS subscales were included as confounders in the 
respective regression models below. These included: infant feeding method for NNNS Self-
Regulation and Handling, and infant ETS and maternal depressive symptoms for NNNS 
Lethargy and Attention.
3.2. Overall impact of MJ+TOB and TOB-exposure on infant neurobehavior over the first 
postnatal month.
No differences among exposure groups emerged with respect to infant age effects over the 
first postnatal month for any NNNS subscale (linear slope x exposure group interaction ps>.
25). Therefore, interest centered upon group differences in outcome levels across NNNS 
exams. After control for confounders, associations with exposure groups emerged for all 
four NNNS subscales in the overall and sex-stratified samples, except for Attention for 
daughters and Lethargy for sons. Associations were negative for Self-Regulation (ps<.001, .
014, .002, respectively) and Attention (ps< .001, .177, .029) and positive for Handling (ps< .
001, .002, .006) and Lethargy (ps<.043, .023, .754).
3.3. Impact of MJ+TOB and TOB-exposure on NNNS Self-Regulation.
As shown in Table 2 and Figure 2A, both MJ+TOB-exposed and TOB-exposed infants 
showed significantly attenuated self-regulation over the first postnatal month vs. unexposed 
infants (ps< .03). Using an estimated residual SD of .70 units for the unexposed group, MJ
+TOB-exposed infants showed nearly twice the impact on self-regulation vs. unexposed 
infants than was shown for TOB-exposed infants. MJ+TOB-exposed infants showed a .357 
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unit decrease (95% CI=.173-.541, p<.001) vs. unexposed infants, and a .185 unit decrease 
(95% CI=.007-.363, p=.043) vs. TOB-exposed infants. TOB-exposed infants showed a .172 
unit (95% CI=.023-.321, p=.025) decrease vs. unexposed infants.
As shown in Table 2 and Figure 3A, stratifying by infant sex revealed a significant (.318 
unit) decrease in self-regulation from TOB-only exposure vs. no exposure for sons (p<.003), 
but not daughters (p=.541). Effects of MJ+TOB vs. no exposure were significant for both 
sexes (ps<.005), but slightly more pronounced for daughters vs. sons (.426 vs .351 unit 
decreases). Finally, daughters (p=.011) but not sons (p=.786) showed a significant difference 
(.357 unit decrease) in the impact of MJ+TOB vs. TOB-only exposure on self-regulation.
3.4. Impact of MJ+TOB and TOB-exposure on NNNS Handling.
As shown in Table 2 and Figure 2B, both MJ+TOB-exposed and TOB-exposed infants 
showed significantly increased need for external handling over the first postnatal month vs. 
unexposed infants. Based on an estimated residual SD of .60 units in the logarithmic scale 
for the unexposed group, MJ+TOB-exposed infants showed nearly 2X the impact on 
handling vs. unexposed infants than did TOB-exposed infants. MJ+TOB-exposed infants 
showed a 32.1% increase in need for handling vs. unexposed infants (95% 
CI=16.2%-50.2%, p<.001) and an 12% increase vs. TOB-exposed infants (95% CI=.99–
1.26, p=.066). TOB-exposed infants showed an 18.1% increase vs. unexposed infants (95% 
CI=6.0%-31.5%, p=.003).
As shown in Table 2 and Figure 3B, stratifying by infant sex revealed a significant (27%) 
increase in need for external handling from TOB-only exposure vs. no exposure for sons 
(p<.003), but not daughters (p=.178). Effects of MJ+TOB vs. no exposure were significant 
for both sexes (ps<.02), but were more pronounced for daughters vs. sons (40% vs. 27% 
increases). Finally, daughters (p=.007), but not sons (p=.963) showed a significant difference 
(26% increase) in the impact of MJ+TOB vs. TOB-only exposure on need for handling.
3.5. Impact of MJ+TOB and TOB-exposure on NNNS Attention.
As shown in Table 2 and Figure 2C, both MJ+TOB-exposed and TOB-exposed infants 
showed significantly decreased attention over the first postnatal month vs. unexposed infants 
(ps<.02). Based on an estimated residual SD of 1.41 units for the Control group, MJ
+TOBexposed infants showed a .626 unit decrease in attention (95% CI=.197–1.055, p=.
005) vs. unexposed infants, while TOB-exposed infants showed a .441 unit decrease (95% 
CI =.081-.802, p=.017). Although differences between MJ+TOB-exposed vs. TOB-exposed 
infants did not attain significance (p=.371) the impact of MJ+TOB was approximately 42% 
greater than the impact of TOB alone.
As shown in Table 2 and Figure 3C, stratifying by sex revealed a significant (.585 unit) 
decrease in attention from TOB-only exposure vs. no exposure for sons (p=.008), but not 
daughters (p=.420). MJ+TOB exposure vs. no exposure led to a trend toward decreased 
attention for daughters (.674 unit decrease; p=.063), but not sons (p=.113). Neither 
daughters nor sons showed significant differences between MJ+TOB and TOB-only 
exposure on attention (ps>.25).
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3.6. Impact of MJ+TOB and TOB-exposure on NNNS Lethargy.
As shown in Table 2 and Figure 2D, MJ+TOB-exposed infants showed a 15% (95% CI = 
3%-28%, p=.014) increase in lethargy over the first postnatal month vs. unexposed infants. 
TOB-exposed infants showed a trend toward increased lethargy vs. unexposed infants (p=.
098). A residual SD of .39 units in the logarithmic scale was estimated for the unexposed 
group. Although no significant differences between MJ+TOB vs. TOB-exposed infants 
emerged (p=.256), the impact of MJ+TOB was 75% greater than TOB alone. As shown in 
Table 2 and Figure 3D, stratifying by infant sex revealed significant increases in lethargy 
from TOB-only exposure (17%) and MJ+TOB exposure (22%) vs. no exposure for 
daughters (ps<.05) but no effects of MJ+TOB or TOB-only for sons (ps>.45). No significant 
difference between MJ+TOB and TOB-only exposure emerged for daughters or sons for 
lethargy (ps>.55).
4. Discussion
We found a significant impact of prenatal co-exposure to marijuana and tobacco (MJ+TOB) 
on newborn neurobehavior using the NNNS, a neurologic and behavioral examination 
sensitive to subtle alterations in behavior in substance-exposed infants (Lester et al., 2004; 
Tronick and Lester, 2013). Specifically, MJ+TOB-exposed infants showed lower ability to 
self-soothe (NNNS Self-regulation) and attend to stimuli (NNNS Attention), and lower 
motor tone and inactivity (NNNS Lethargy), and greater need for external soothing (NNNS 
Handling) versus unexposed infants over the first postnatal month. Despite low levels of MJ 
co-use and similar TOB use levels between MJ+TOB and TOB groups, MJ+TOB co-
exposure was associated with nearly double the impact on infant self-soothing and need for 
examiner soothing versus TOBexposure alone, and with a 42–75% increased impact on 
infant attention and lethargy versus TOB-exposure alone. Finally, we found sex-specific 
effects of MJ+TOB; such that effects of coexposure on self-soothing, need for external 
soothing, attention, and lethargy were more pronounced for daughters versus sons.
NNNS Self-Regulation measures newborns’ capacity to self-soothe, or their ability to 
organize motor activity, physiology, and state in response to manipulation and stimulus 
presentations during the exam. Conversely, NNNS Handling measures newborns’ need for 
external soothing, or their need for intervention from the examiner to soothe the infant and 
assist the infant in maintaining a quiet, alert state. MJ+TOB co-exposure resulted in 
significant decreases in self-soothing and increases in need for examiner soothing versus no 
substance exposure. Moreover, MJ+TOB co-exposure was associated with nearly 200% 
increased impact versus TOB exposure alone on self-soothing and need for examiner 
soothing. Results complement a recent MJ+TOB co-exposure study which revealed 
associations between coexposure and less adaptive autonomic regulation in nine-month old 
infants (Eiden et al., 2018). Results also complement prior studies of TOB-exposure alone, 
which showed increased irritability, alterations in regulatory processes and increased need 
for external soothing across the first postnatal month (Espy et al., 2011; Stroud et al., 2009a; 
Stroud et al., 2009b; Yolton et al., 2009). Our findings are also consistent with some prior 
prenatal MJ exposure studies that revealed increases in irritability and decreases in self-
regulation in the early newborn period (de Moraes Barros et al., 2006; Fried, 1980; Fried and 
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Makin, 1987). Our newborn findings are inconsistent with a prior co-exposure study focused 
on 9-month-old infants, demonstrating no direct effects of prenatal MJ+TOB on infant 
regulation (Schuetze et al., 2018). Thus, it is possible that MJ+TOB effects demonstrated in 
the current study are transitory—potentially related to withdrawal processes or neural 
development specific to the newborn period—and dissipate by later infancy. Future studies 
are needed to replicate current findings and to elucidate the evolution of prenatal co-
exposure effects over the first postnatal year.
Prenatal co-exposure to MJ+TOB also resulted in significant decreases in newborn attention 
and increases in lethargy versus no substance exposure. NNNS Attention is a measure of 
orientation to animate and inanimate auditory and visual stimuli; NNNS Lethargy is a 
measure of infant lethargic behavior or low levels of motor, state, and physiologic reactivity. 
Although differences between MJ+TOB versus TOB-only exposure were not statistically 
significant for either attention or lethargy, MJ+TOB exposure was associated with a 42% 
increased impact on newborn attention and a 75% increased impact on lethargy. Effects on 
newborn attention complement prior cross-sectional and longitudinal studies of prenatal 
TOB (Espy et al., 2011; Mansi et al., 2007). Although effects of prenatal TOB have been 
somewhat inconsistent in early infancy (Law et al., 2003; Stroud et al., 2009b; Yolton et al., 
2009), one of the more consistent long-term effects of prenatal TOB is its association with 
child attention deficits, ADHD, and deficits in executive function (Huang et al., 2018; 
Micalizzi and Knopik, 2017). In contrast, prior studies of prenatal MJ did not show effects 
on attention in the newborn period (de Moraes Barros et al., 2006; Fried, 1980; Fried and 
Makin, 1987), although effects on long-term attention and executive function deficits have 
been shown (El Marroun et al., 2011; Smith et al., 2006; Smith et al., 2016).
We can speculate about potential mechanisms underlying effects of MJ+TOB on infant 
development. First, it is possible MJ+TOB co-exposure effects are due to increased exposure 
to TOB/cigarettes in the MJ+TOB group. However, we found nearly identical average 
cigarettes per day in the MJ+TOB versus the TOB-only group (M=7±6 per day for both 
groups). Similarly, it is possible that co-exposure effects are due to increased exposure to 
nicotine and/or combustion. The majority of MJ+TOB users in our sample endorsed 
smoking MJ (e.g., joints, bowls, blunts) versus other methods of use (edibles, vaping) 
suggesting increased exposure to combustion. Further, approximately 42% endorsed use of 
blunts (partially or fully hollowed cigar wrappers filled with marijuana), which contain 
measurable amounts of nicotine and increase in carbon monoxide levels relative to joints 
(Cooper and Haney, 2009; Peters et al., 2016). However, we found no differences between 
MJ+TOB and TOB groups in 3rd trimester cotinine (nicotine metabolite) or carbon 
monoxide levels (marker of exposure to combustion). Nonetheless, because most MJ use 
took place during 1st trimester in this sample, it is possible that effects of co-use may be 
related to increased nicotine or combustion exposure in early gestation.
Another possibility is that exposure to MJ+TOB (vs. TOB only) may not only disrupt 
nicotinic pathways, but also additional pathways in the fetal brain, leading to more profound 
alterations in neurodevelopment. THC crosses the placenta and exerts its biological 
functions through binding to cannabinoid receptors (Type 1: CB1, and Type 2: CB2) in the 
endocannabinoid system, which are present in early fetal development (Bailey et al., 1987; 
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Matsuda et al., 1990; Munro et al., 1993; Parsons and Hurd, 2015; Richardson et al., 2016). 
The fetal endocannabinoid system regulates several aspects of neural development, 
including neurogenesis, neuronal migration, neurite outgrowth and axonal pathfinding 
(Vitalis et al., 2008). Preclinical studies have revealed pernicious effects of prenatal THC on 
neuronal development via disruption of endocannabinoid signaling pathways (de Salas-
Quiroga et al., 2015; Szutorisz et al., 2014; Tortoriello et al., 2014). Synergistic effects of 
prenatal TOB/nicotine and MJ/THC on glucocorticoid and reward signaling pathways and/or 
epigenetic pathways are also plausible (del Arco et al., 2000; Morris et al., 2011; Szutorisz 
and Hurd, 2016, 2018).
Finally, it is possible that co-exposure effects on offspring outcomes are due to differences in 
characteristics of MJ+TOB co-users vs. sole TOB users and controls. Although relevant 
demographic characteristics were statistically controlled, it is possible that there were 
unmeasured genetic or personality differences that may lead to both maternal MJ+TOB co-
use and alterations in infant neurobehavior. Future studies with genetically sensitive designs 
are needed to tease apart interactions between maternal exposures and maternal 
characteristics/ genetics on offspring neurobehavioral outcomes (Bidwell et al., 2016; 
D'Onofrio et al., 2014; Fang et al., 2010).
Our exploratory analyses of sex-specific effects of prenatal MJ+TOB revealed an overall 
more pronounced impact of co-exposure on newborn neurobehavior for daughters versus 
sons. Specifically, although effects of MJ+TOB on self-regulation and need for external 
handling were statistically significant for both sexes, effects were 20% and 50% greater for 
daughters than sons, respectively. For attention and lethargy, effects of co-exposure were 
significant for daughters only--not sons. Daughter-specific effects of MJ+TOB complement 
a study of prenatal MJ and attention and aggression in 18-month olds in which MJ effects 
were only significant for daughters, and the majority of MJ-exposed infants were co-exposed 
to prenatal TOB (El Marroun et al., 2011). In contrast, we found that effects of prenatal TOB 
alone on newborn neurobehavior were specific to sons for most neurobehavioral scales. In 
particular, prenatal TOB was associated with decreased self-regulation, increased need for 
handling, and decreased attention in sons but not daughters. Son-specific prenatal TOB 
effects on newborn behavioral dysregulation are consistent with prior studies highlighting 
son-specific prenatal TOB effects on risk for offspring disruptive behavior disorders in older 
offspring (Brennan et al., 2002; Fergusson et al., 1998; Weissman et al., 1999). Although 
replication of the current pattern of sexspecific findings is needed, we can speculate on 
mechanisms. Potential mechanisms may include: (a) sex hormone modulation of effects of 
THC+nicotine vs nicotine on fetal neuronal development, (b) sexual differentiation of 
emerging fetal brain structures and function may lead to differential impact of THC+nicotine 
vs nicotine by fetal sex, (c) sex differences in placental structure and function may modulate 
passage of THC+nicotine vs nicotine to the developing fetus, (d) sex differences in genetic 
or epigenetic pathways that regulate response to environmental cues, and (e) fetal sex-
influenced differences in the maternal hormonal milieu (Clifton, 2010; Cross et al., 2017; 
DiPietro and Voegtline, 2017; Sundram, 2006). Large-scale longitudinal studies powered to 
investigate interactions of substance exposures and offspring sex are needed to delineate sex-
specific developmental trajectories of coherent, narrow band phenotypes (Wakschlag et al., 
2018) following prenatal co-exposures as well as underlying mechanisms. Comprehensive 
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theories are also needed to better integrate relatively inconsistent patterns of findings with 
respect to offspring sex within and across exposures, offspring phenotypes, and even species 
(e.g., (Sandman et al., 2013).
We acknowledge several additional limitations that provide directions for future research. 
Key limitations relate to our use of a sample selected to understand maternal tobacco use— 
including the small number of MJ+TOB co-users (n=24) and low levels of MJ use. However, 
that MJ+TOB co-use effects emerged despite the small co-use sample and low co-use levels 
suggests that even larger effects might emerge in a larger sample with greater levels and 
more prolonged MJ co-use. Further, although we compared the impact of prenatal MJ+TOB 
coexposure to TOB-only exposure, we did not have a MJ-only exposure group. Future 
studies need to include both TOB-only and MJ-only groups to determine the unique and 
synergistic impacts of MJ and TOB exposures on offspring development. Finally, the present 
analyses focused on group differences in the impact of any MJ+TOB and TOB-only 
exposure on infant neurobehavior. Future dose-response studies are needed to determine the 
quantitative impact of MJ/THC and TOB/nicotine on infant neurobehavior.
Findings from the present study highlight the importance of explicitly characterizing the 
impact of substance co-exposures on infant outcomes. While single exposure studies (where 
effects of other substances are controlled through group inclusion criteria and/or statistical 
techniques) are needed to determine specific effects of any given substance, studies designed 
to investigate co-exposures also offer potential to inform obstetric providers and pregnant 
mothers regarding offspring outcomes following “real-world” co-use behaviors. Future 
studies are also needed to explicitly characterize potential additive or multiplicative effects 
of additional substance exposures and non-substance exposures including environmental 
toxins, poverty, stress, and mental health problems (Clark et al., 2016; Stroud et al., 2014b).
Our findings also have implications for intervention and prevention efforts. The first month 
is an important period for development of mother-infant attachment. The combination of a 
lethargic infant requiring additional external soothing and a co-using mother with fewer 
resources and parenting skills could disrupt maternal-infant interactions during this critical 
period. Alterations in newborn behavior may themselves portend adverse long-term 
outcomes; however, more likely is that subtle differences in newborn behavior in the context 
of a less resourced parent may lead to a maladaptive cycle of continued behavioral 
dysregulation, further disruptions in maternal-infant attachment, and eventually, long-term 
adverse offspring outcomes (Beeghly et al., 2016; Beeghly and Tronick, 1994; Blackwell et 
al., 1998; Lester et al., 2009).Results highlight the need for early identification, intervention 
and education efforts for parents of exposed/co-exposed infants to prevent disruptions in 
early mother-infant attachment and to assist in facilitating self-regulatory skill development. 
Results also highlight the need to assess MJ co-use in pregnant TOB users and to educate 
pregnant TOB-users regarding potential risks of MJ co-use. The adverse effects of prenatal 
TOB have received a great deal of public health attention (England et al., 2017b; Haviland et 
al., 2004; Orleans et al., 2004); however, despite increasing availability and use of MJ, both 
pregnant women and obstetric providers report a dearth of available information regarding 
effects of prenatal MJ use on mothers and offspring (Holland et al., 2016a; Holland et al., 
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2016b; Jarlenski et al., 2016). Novel interventions are also needed to address both TOB use 
and MJ co-use.
4.1. Conclusions
Our findings suggest that the profile of a MJ+TOB co-exposed infant in the newborn period 
includes greater difficulty in self-soothing, greater need for external soothing, poorer 
attention to stimuli, and greater lethargy. Alterations in newborns’ ability to self-soothe and 
need for external soothing were nearly 2X greater for MJ+TOB exposure versus TOB 
exposure alone. Results highlight additional risks of dual exposure to MJ+TOB versus TOB 
exposure alone and the importance of explicitly characterizing prenatal substance exposures 
in concert and in context. Results also highlight the need for intervention efforts to address 
MJ co-use in pregnant TOB users and for early identification of co-exposed infants.
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• Investigated the impact of marijuana and tobacco co-use in pregnancy on 
newborn behavior.
• Newborns exposed to both marijuana and tobacco showed decreased ability to 
self-soothe and attend to stimuli.
• Co-exposed newborns also needed more external soothing and were more 
lethargic.
• Effects of co-exposure were worse for daughters than for sons.
• Intervention efforts to address marijuana co-use in pregnant tobacco users are 
needed.
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Overview of the Behavior and Mood in Babies and Mothers (BAM BAM) study. Note: 
CO=Breath Carbon Monoxide assessment; NNNS=NICU Network Neurobehavioral Scale.
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Infant Neurobehavior over the first Postnatal Month in MJ+TOB-exposed, TOBexposed, and 
unexposed infants: (a) NICU Network Neurobehavioral Scale (NNNS) SelfRegulation, (b) 
NNNS Handling, (c) NNNS Attention, (d) NNNS Lethargy. The NICU Network 
Neurobehavioral Scale (NNNS) was administered up to 7 times over the first postnatal 
month at days 0 (M=8 hours), 1, 2, 4, 5, 11, and 32. NNNS Lethargy and NNNS Handling 
were modeled in the logarithmic scale.
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Infant Neurobehavior over the first Postnatal Month in MJ+TOB-exposed, TOBexposed, and 
unexposed daughters and sons: (a) NICU Network Neurobehavioral Scale (NNNS) Self-
Regulation, (b) NNNS Handling, (c) NNNS Attention, (d) NNNS Lethargy.
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Table 1.
Maternal and infant characteristics by tobacco (TOB) and marijuana (MJ) exposure group and full sample.
Controls (n=42) 
Mean (SD)/ %




Total (n=11) Mean 
(SD)/ %
Maternal Characteristics
Age (years) 25 (6) 24 (4) 25 (4) 25 (5)
Race/Ethnicity (% Non-Hispanic White) 42% 53% 42% 46%
Low SES
1 20% 47% 65% 40%***
Gravida 2.3 (1.6) 2.9 (2.2) 2.6 (1.4) 2.6 (1.8)
Parity 1.0 (1.2) 1.2 (1.5) 1.1 (1.4) 1.1 (1.4)
Weight gain (pounds)
2 33 (17) 27 (18) 32 (13) 31 (17)
Alcohol Use (>1 drink/week) 0% 4% 17% 5%*
Caffeine Use (>200 mg/day caffeine)
3 5% 39% 21% 22%***
High ETS Exposure (>1 hour/day)
4 2% 59% 29% 40%***
Gestational Medical Conditions
5 7% 22% 17% 15%
Depressive Symptoms
6 2 (3) 5 (5) 6 (6) 4 (5)**
Tobacco Use (cigs/day)
7 0 (0) 7.3 (6.2) 6.8 (5.4) ---
Maternal Cotinine per day (ng/mL)
7 0 (0) 96 (111) 75 (91) ---
Maternal Carbon Monoxide (ppm)
7 1 (1) 6 (5) 4 (3) ---
Infant Characteristics
Sex (% female) 40% 51% 46% 46%
Delivery Mode (% vaginal delivery) 76% 78% 79% 77%
Gestational age at birth (weeks) 40 (1) 40 (1) 40 (1) 40 (1)
Small for gestational age
8 2% 7% 4% 5%
Apgar score (> 8 at 5 minutes) 90% 98% 96% 95%
Any breastfeeding 81% 56% 46% 62%
ETS Exposure: saliva cotinine (ng/ml)








Based on a score of 4 or 5 on the Hollingshead Index.
2
Weight gain in pounds between pre-pregnancy and 35±1 weeks.
3
Equivalent of two cups of coffee per day.
4
Hours of environmental tobacco smoke exposure per week measured by structured interview.
5
e.g., gestational hypertension, gestational diabetes.
6
Score on 21-item Hamilton Depression Rating Scale.
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7
No significant differences between tobacco-only and marijuana+tobacco groups
8
Birthweight <10th percentile for gestational age.
9
Environmental Tobacco Smoke exposure measured by infant saliva cotinine at postnatal day 32 (ng/ml).
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Table 2.
Impact of marijuana+tobacco (MJ+TOB) co-use and sole tobacco (TOB) use on newborn neurobehavior over 
the first postnatal month for the full sample (n=111) and for daughters (n=51) and sons (n=60).
Predictor Variables Full Sample Daughters Sons
β SE p β SE p β SE p
Self-Regulation
1
Intercept 5.334 .219 <.001 5.144 .297 <.001 5.543 .317 <.001
Infant age
6 .092 .023 <.001 .090 .033 .007 .098 .032 .002
Time since feeding
7 −.020 .035 .569 .040 .046 .387 −.074 .051 .147
Any Breastfeeding −.193 .073 .008 −.203 .107 .058 −.232 .099 .020
Tobacco −.172 .076 .025 −.069 .112 .541 −.318 .106 .003
Marijuana + Tobacco −.357 .094 <.001 −.426 .151 .005 −.351 .119 .003
MJ+TOB vs. TOB
Difference −.185 .091 .043 −.357 .140 .011 −.033 .122 .786
Handling
2,5
Intercept .983 .180 <.001 .960 .244 <.001 .956 .264 <.001
Infant age
6 −.065 .018 <.001 −.075 .025 .003 −.053 .026 .039
Time since feeding
7 .053 .030 .079 .062 .042 .141 .044 .043 .313
Any Breastfeeding .140 .050 .005 .177 .071 .013 .151 .072 .038
Tobacco .166 .055 .003 .103 .076 .178 .242 .080 .003
Marijuana + Tobacco .278 .066 <.001 .334 .092 <.001 .237 .094 .012
MJ+TOB vs. TOB .112 .061 .066 .231 .086 .007 −.004 .087 .963
Attention
3
Intercept 3.455 .439 <.001 2.272 .565 <.001 4.390 .612 <.001
Infant age
6 .337 .052 <.001 .400 .072 <.001 .296 .068 <.001
Time since feeding
7 .156 .068 .023 .339 .082 <.001 .002 .099 .983
Infant ETS
8 −.010 .004 .023 −.006 .008 .491 −.018 .005 .001
Depression Score
9 −.058 .016 <.001 −.041 .029 .153 −.076 .021 <.001
Tobacco −.441 .184 .017 −.257 .318 .420 −.585 .219 .008
Marijuana + Tobacco −.626 .219 .005 −.674 .361 .063 −.465 .292 .113




2.447 .119 <.001 2.426 .175 <.001 2.418 .161 <.001
Infant age
6 −.132 .013 <.001 −.134 .019 <.001 −.128 .018 <.001
Time since feeding
7 −.055 .020 .006 −.054 .030 .078 −.052 .027 .054
Infant ETS
8 .002 .001 .031 −.001 .002 .700 .005 .001 .001
Depression Score
9 .013 .004 .002 .008 .006 .197 .019 .006 .001
Tobacco .077 .047 .098 .158 .070 .025 .027 .062 .664
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Marijuana + Tobacco .136 .055 .014 .201 .079 .011 .059 .079 .455
MJ+TOB vs. TOBDifference .058 .051 .256 .044 .074 .553 .032 .072 .656
Note:Reference group is unexposed infants for the overall model. Red, italicized coefficients show differences between MJ+TOB versus TOB-
exposed infants.
1
NICU Network Neurobehavioral Scale (NNNS) Self-Regulation measures the infant’s capacity to organize motor activity, physiology, and state in 
response to manipulation and stimulus presentations throughout the exam;
2
NNNS Handling is a measure of need for intervention from the NNNS examiner to soothe the infant and assist the infant in maintaining a quiet, 
alert state.
3
NNNS Attention is a measure of orientation to animate and inanimate auditory and visual stimuli.
4
NNNS Lethargy is a measure of low levels of motor, state and physiologic reactivity.
5
NNNS Lethargy and NNNS Handling were natural log transformed.
6
Infant age (measured in hours).
7
Time since feeding (measured in mins).
8
Infant Environmental Tobacco Smoke (ETS) exposure measured by saliva cotinine (ng/ml).
9
Maternal depressive symptoms on 21-item Hamilton Depression Rating Scale.
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